143 related articles for article (PubMed ID: 37202293)
1. [Uterin adenosarcoma: French Guidelines of the French Sarcoma Group and the Rare Gynecologic Tumor Group].
Karabajakian A; Genestie C; Meeus P; Guyon F; Llacer Moscardo C; Croce S; Taieb S; Duffaud F; Pautier P; Ray-Coquard I; Blay JY
Bull Cancer; 2023; 110(7-8):836-843. PubMed ID: 37202293
[TBL] [Abstract][Full Text] [Related]
2. Uterine Adenosarcoma.
Ulrich UA; Denschlag D
Oncol Res Treat; 2018; 41(11):693-696. PubMed ID: 30326467
[TBL] [Abstract][Full Text] [Related]
3. Mullerian adenosarcoma: a clinicopathologic and immunohistochemical study of 55 cases challenging the existence of adenofibroma.
Gallardo A; Prat J
Am J Surg Pathol; 2009 Feb; 33(2):278-88. PubMed ID: 18941402
[TBL] [Abstract][Full Text] [Related]
4. Uterine Adenosarcoma: a Review.
Nathenson MJ; Ravi V; Fleming N; Wang WL; Conley A
Curr Oncol Rep; 2016 Nov; 18(11):68. PubMed ID: 27718181
[TBL] [Abstract][Full Text] [Related]
5. Gynecologic Cancer InterGroup (GCIG) consensus review for mullerian adenosarcoma of the female genital tract.
Friedlander ML; Covens A; Glasspool RM; Hilpert F; Kristensen G; Kwon S; Selle F; Small W; Witteveen E; Russell P
Int J Gynecol Cancer; 2014 Nov; 24(9 Suppl 3):S78-82. PubMed ID: 25341585
[TBL] [Abstract][Full Text] [Related]
6. High-grade Müllerian Adenosarcoma: Genomic and Clinicopathologic Characterization of a Distinct Neoplasm With Prevalent TP53 Pathway Alterations and Aggressive Behavior.
Hodgson A; Amemiya Y; Seth A; Djordjevic B; Parra-Herran C
Am J Surg Pathol; 2017 Nov; 41(11):1513-1522. PubMed ID: 28834809
[TBL] [Abstract][Full Text] [Related]
7. Mullerian adenosarcoma of the female genital tract.
McCluggage WG
Adv Anat Pathol; 2010 Mar; 17(2):122-9. PubMed ID: 20179434
[TBL] [Abstract][Full Text] [Related]
8. Management of uterine adenosarcomas with and without sarcomatous overgrowth.
Tanner EJ; Toussaint T; Leitao MM; Hensley ML; Soslow RA; Gardner GJ; Jewell EL
Gynecol Oncol; 2013 Apr; 129(1):140-4. PubMed ID: 23283300
[TBL] [Abstract][Full Text] [Related]
9. Uterine adenosarcoma with sarcomatous overgrowth versus uterine carcinosarcoma: comparison of treatment and survival.
Krivak TC; Seidman JD; McBroom JW; MacKoul PJ; Aye LM; Rose GS
Gynecol Oncol; 2001 Oct; 83(1):89-94. PubMed ID: 11585418
[TBL] [Abstract][Full Text] [Related]
10. Feasibility of uterine preservation in the management of early-stage uterine adenosarcomas: a single institute experience.
Lee YJ; Kim DY; Suh DS; Kim JH; Kim YM; Kim YT; Nam JH
World J Surg Oncol; 2017 Apr; 15(1):87. PubMed ID: 28424089
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical markers and the clinical course of adenosarcoma: a series of seven cases.
Omi M; Tonooka A; Chiba T; Tanaka Y; Fusegi A; Aoki Y; Nomura H; Kanao H; Takazawa Y
Diagn Pathol; 2020 Sep; 15(1):119. PubMed ID: 32972432
[TBL] [Abstract][Full Text] [Related]
12. Cluster of uterine mullerian adenosarcoma in the Washington, DC metropolitan area with high incidence of sarcomatous overgrowth.
Seidman JD; Wasserman CS; Aye LM; MacKoul PJ; O'Leary TJ
Am J Surg Pathol; 1999 Jul; 23(7):809-14. PubMed ID: 10403304
[TBL] [Abstract][Full Text] [Related]
13. Imaging findings of uterine adenosarcoma with sarcomatous overgrowth: two case reports, emphasizing restricted diffusion on diffusion weighted imaging.
Nakai G; Matsutani H; Yamada T; Ohmichi M; Yamamoto K; Osuga K
BMC Womens Health; 2021 Dec; 21(1):416. PubMed ID: 34915866
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical determination of estrogen and progesterone receptor positivity in uterine adenosarcoma.
Amant F; Schurmans K; Steenkiste E; Verbist L; Abeler VM; Tulunay G; De Jonge E; Massuger L; Moerman P; Vergote I
Gynecol Oncol; 2004 Jun; 93(3):680-5. PubMed ID: 15196864
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors for uterine adenosarcoma: a review.
Nathenson MJ; Conley AP
Expert Rev Anticancer Ther; 2018 Nov; 18(11):1093-1100. PubMed ID: 30169984
[TBL] [Abstract][Full Text] [Related]
16. Italian consensus conference on management of uterine sarcomas on behalf of S.I.G.O. (Societa' italiana di Ginecologia E Ostetricia).
Ferrandina G; Aristei C; Biondetti PR; Cananzi FCM; Casali P; Ciccarone F; Colombo N; Comandone A; Corvo' R; De Iaco P; Dei Tos AP; Donato V; Fiore M; Franchi ; Gadducci A; Gronchi A; Guerriero S; Infante A; Odicino F; Pirronti T; Quagliuolo V; Sanfilippo R; Testa AC; Zannoni GF; Scambia G; Lorusso D
Eur J Cancer; 2020 Nov; 139():149-168. PubMed ID: 32992154
[TBL] [Abstract][Full Text] [Related]
17. [Prognosis-related clinicopathologic characteristics of FIGO stage Ⅰ Müllerian adenosarcoma of uterus].
Wang Y; Liu AJ; Chen X; Song X
Zhonghua Bing Li Xue Za Zhi; 2018 May; 47(5):334-338. PubMed ID: 29783798
[No Abstract] [Full Text] [Related]
18. Primary vaginal adenosarcoma with sarcomatous overgrowth.
Toyoshima M; Akahira J; Moriya T; Hayakawa S; Yaegashi N
Gynecol Oncol; 2004 Dec; 95(3):759-61. PubMed ID: 15582000
[TBL] [Abstract][Full Text] [Related]
19. Uterine Adenosarcoma with Sarcomatous Overgrowth and Rhabdoid Features: A Rare Case.
Rashid S; Akhtar M
Saudi J Med Med Sci; 2022; 10(1):72-76. PubMed ID: 35283707
[TBL] [Abstract][Full Text] [Related]
20. Post-radiation Mullerian adenosarcoma with sarcomatous overgrowth: rare presentation of an uncommon malignancy.
Mubeen A; Shahid M; Makary R
Pathologica; 2020 Dec; 112(4):219-223. PubMed ID: 33393526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
